Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD
Novel subcutaneous delivery may offer a more patient-friendly…Read More
You might also be interested in reading $1 Million Bitcoin Is Coming: Arthur Hayes Says Fed Just Pulled The Trigger.